Jacobs Levy Equity Management Inc. Purchases Shares of 977,920 Kura Oncology, Inc. (NASDAQ:KURA)

Jacobs Levy Equity Management Inc. purchased a new stake in Kura Oncology, Inc. (NASDAQ:KURA - Free Report) in the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor purchased 977,920 shares of the company's stock, valued at approximately $8,518,000. Jacobs Levy Equity Management Inc. owned 1.26% of Kura Oncology as of its most recent SEC filing.

Several other large investors also recently made changes to their positions in the stock. RA Capital Management L.P. bought a new stake in shares of Kura Oncology in the 4th quarter valued at about $38,769,000. Marshall Wace LLP acquired a new stake in shares of Kura Oncology in the fourth quarter valued at approximately $8,265,000. D. E. Shaw & Co. Inc. grew its holdings in shares of Kura Oncology by 172.0% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 1,151,195 shares of the company's stock worth $10,027,000 after purchasing an additional 727,987 shares in the last quarter. Vanguard Group Inc. lifted its holdings in shares of Kura Oncology by 14.6% during the 4th quarter. Vanguard Group Inc. now owns 4,818,898 shares of the company's stock worth $41,973,000 after acquiring an additional 615,211 shares during the period. Finally, Algert Global LLC boosted its stake in Kura Oncology by 224.6% in the fourth quarter. Algert Global LLC now owns 883,703 shares of the company's stock valued at $7,697,000 after buying an additional 611,427 shares in the last quarter.

Wall Street Analysts Forecast Growth

KURA has been the topic of a number of research reports. Barclays reduced their price objective on Kura Oncology from $32.00 to $11.00 and set an "overweight" rating on the stock in a research report on Friday, May 2nd. BTIG Research downgraded Kura Oncology from a "buy" rating to a "neutral" rating in a research note on Thursday, February 6th. JMP Securities restated a "market outperform" rating and set a $28.00 target price on shares of Kura Oncology in a research report on Tuesday, April 29th. StockNews.com cut Kura Oncology from a "buy" rating to a "hold" rating in a research note on Friday, May 2nd. Finally, Wedbush reissued an "outperform" rating and issued a $36.00 price target on shares of Kura Oncology in a research note on Tuesday, April 8th. Four analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $23.89.

Kura Oncology Stock Up 1.9%

Shares of NASDAQ KURA traded up $0.12 during midday trading on Monday, hitting $6.14. 379,739 shares of the stock traded hands, compared to its average volume of 1,176,640. The company has a debt-to-equity ratio of 0.02, a quick ratio of 11.47 and a current ratio of 11.47. Kura Oncology, Inc. has a one year low of $5.41 and a one year high of $23.48. The business has a 50 day moving average price of $6.42 and a two-hundred day moving average price of $8.72. The company has a market cap of $531.14 million, a PE ratio of -2.60 and a beta of 0.50.

Kura Oncology (NASDAQ:KURA - Get Free Report) last announced its quarterly earnings results on Thursday, May 1st. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.51) by ($0.15). The business had revenue of $14.11 million for the quarter, compared to analyst estimates of $39.08 million. On average, equities analysts predict that Kura Oncology, Inc. will post -2.44 EPS for the current year.

About Kura Oncology

Kura Oncology, Inc, a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's pipeline consists of small molecule product candidates that target cancer. Its lead product candidates are ziftomenib, an orally bioavailable small molecule inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a farnesyl transferase inhibitor for the treatment of solid tumors.